Novavax's Second-Largest Shareholder Sells $32.6 Million in Stock, Ends Activist Push
Key takeaways
- Shah Capital’s sale ends its activist push, leaving Novavax with a large passive shareholder but less pressure for a sale or board changes.
- 2.87 million shares sold
- $32.6 million sale value
- average price $11.3486 per share
What happened
Shah Capital, Novavax’s second‑largest shareholder, sold 2.87 million shares for about $32.6 million and announced it will stop trying to influence the company’s control, shifting to a family office structure. The sale was made at an average price of $11.3486 per share on Oct. 5, and the firm withdrew its investment‑adviser registration. Shah retains about 10.66 million shares (6.46 % of NVAX) and will report its holdings under a passive 13G filing.
Why it matters
The move ends a prolonged activist campaign that had pushed for a sale of Novavax and for board and compensation changes. It signals a shift in shareholder strategy that could reduce pressure on management and alter the company’s governance dynamics. The sale also reflects Shah’s assessment that Novavax’s vaccine…
Short-term and longer-term
Short-term. In the next few days, watch for any shift in NVAX’s share price as the market digests the end of activist pressure.
Longer-term. Over the coming months, the change in shareholder activism could affect NVAX’s strategic direction, particularly its pursuit of a sale or partnership.